XNASFTRE
Market cap1.63bUSD
Jan 10, Last price
18.19USD
1D
-1.20%
1Q
-3.91%
IPO
-50.62%
Name
Fortrea Holdings Inc
Chart & Performance
P/E
—
P/S
0.52
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
3.11b
+0.42%
Net income
-3m
L
CFO
167m
+91.31%
Earnings
Mar 10, 2025
Profile
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | 3,109,000 0.42% | 3,096,100 1.26% | ||
Cost of revenue | 2,685,000 | 2,474,400 | ||
Unusual Expense (Income) | ||||
NOPBT | 424,000 | 621,700 | ||
NOPBT Margin | 13.64% | 20.08% | ||
Operating Taxes | 4,500 | 500 | ||
Tax Rate | 1.06% | 0.08% | ||
NOPAT | 419,500 | 621,200 | ||
Net income | (3,400) -105.82% | 58,400 -40.41% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | ||||
BB yield | ||||
| Debt | ||||
Debt current | 65,100 | 23,300 | ||
Long-term debt | 1,718,400 | 103,500 | ||
Deferred revenue | ||||
Other long-term liabilities | 61,300 | 21,700 | ||
Net debt | 1,674,900 | 14,800 | ||
| Cash flow | ||||
Cash from operating activities | 167,400 | 87,500 | ||
CAPEX | (40,300) | (54,400) | ||
Cash from investing activities | (31,800) | (54,000) | ||
Cash from financing activities | (139,000) | (8,700) | ||
FCF | 327,100 | 379,900 | ||
| Balance | ||||
Cash | 108,600 | 112,000 | ||
Long term investments | ||||
Excess cash | ||||
Stockholders' equity | (267,400) | (552,000) | ||
Invested Capital | 3,765,000 | 3,940,200 | ||
ROIC | 10.89% | 16.45% | ||
ROCE | 11.63% | 17.40% | ||
| EV | ||||
Common stock shares outstanding | 88,800 | 91,100 | ||
Price | 34.90 | |||
Market cap | 3,099,120 | |||
EV | 4,774,020 | |||
EBITDA | 520,400 | 714,400 | ||
EV/EBITDA | 9.17 | |||
Interest | 69,800 | 132,400 | ||
Interest/NOPBT | 16.46% | 21.30% | ||